Selegiline Side Effects: Risks and Drug Interactions

Selegiline is generally well tolerated, but its side effects range from mild annoyances like insomnia and nausea to serious risks that depend heavily on dose, delivery method, and what other drugs you take alongside it. When used alone at standard doses for Parkinson’s disease, the most frequently reported problems are insomnia, nausea, benign cardiac rhythm changes, dizziness, and headache.¹ The picture gets more complicated when selegiline is combined with levodopa or other medications, and some of the drug’s quirks trace back to what your body actually turns selegiline into after you swallow it.

Why Insomnia Is So Common

If you look at selegiline’s side effect profile, sleep trouble stands out. This isn’t random. After you take selegiline by mouth, your liver rapidly breaks it down into two active byproducts: l-methamphetamine and l-amphetamine. These are less potent than their d-isomer counterparts (the ones associated with stimulant abuse), but they’re still stimulants. Circulating levels of these metabolites in the blood are actually much higher than levels of selegiline itself, and animal research has shown that the time course of wakefulness after a dose closely tracks the rise and fall of these metabolites in the brain.² These same metabolites may also contribute to the mild euphoria some people experience on selegiline, though boosting dopamine activity (especially when levodopa is on board) likely plays a role too.³

The practical takeaway: if insomnia is a problem for you on selegiline, taking your dose in the morning (and a second dose, if prescribed, no later than noon) can help keep those stimulant metabolites from peaking at bedtime. This is one of the most common pieces of advice prescribers give, and it stems directly from the drug’s unusual metabolism.

Blood Pressure Problems You Might Not Expect

Orthostatic hypotension, the dizziness or lightheadedness you feel when you stand up, is a well-documented side effect in people with Parkinson’s disease taking selegiline. This can catch people off guard because classic MAO-B inhibitors aren’t typically associated with major blood pressure swings. But research has found that selegiline dampens autonomic cardiovascular responses, particularly those driven by the sympathetic nervous system. In tilt-table testing, people on selegiline showed a bigger drop in both systolic and diastolic blood pressure after changing position compared to those on placebo.⁴

A small but revealing study found that six out of twenty Parkinson’s patients on selegiline developed marked orthostatic hypotension during head-up tilting, and one patient actually lost consciousness with blood pressure dropping too low to measure. The good news: after stopping selegiline, the orthostatic effect improved within about four days and was gone entirely by seven days.⁵ That same study noted something previously unrecognized: selegiline also raised supine blood pressure, meaning lying-down readings were higher than expected while on the drug, and they dropped after discontinuation.

Separate research confirmed this pattern, showing that withdrawing selegiline led to a significant decrease in supine systolic blood pressure and a smaller initial blood pressure drop when standing.⁶ This matters because Parkinson’s disease itself often causes autonomic dysfunction, so selegiline can layer an additional blood pressure problem on top of one the disease already creates. If you’re prone to dizziness when standing, your doctor should know you’re on selegiline, and getting up slowly from a seated or lying position is basic advice worth following.

The Tyramine Question and Dose-Dependent Selectivity

One of the best-known dangers of older monoamine oxidase inhibitors is the “cheese effect,” where eating tyramine-rich foods (aged cheese, cured meats, fermented products, certain wines) can trigger a dangerous spike in blood pressure. Selegiline at standard oral doses (typically 5 mg twice daily for Parkinson’s) mostly avoids this problem because it selectively inhibits MAO-B rather than MAO-A, and it’s the MAO-A enzyme in the gut that normally breaks down tyramine from food.

But selectivity isn’t absolute, and it erodes at higher doses. Research using oral tyramine challenge testing found that higher-dose selegiline treatment produced a two- to four-fold increase in tyramine sensitivity, along with biochemical evidence that some MAO-A inhibition was emerging.⁷ This means that at standard Parkinson’s doses, strict tyramine dietary restrictions are generally unnecessary. But if you’re on a higher dose, or if your doctor is pushing the dose upward, the risk starts creeping toward the territory of older, nonselective MAO inhibitors. Some clinicians and patients still follow dietary precautions out of caution, which isn’t unreasonable even at lower doses, especially if other medications are in the mix.

Serotonin Syndrome and Drug Interactions

The most dangerous interaction to be aware of involves serotonin syndrome, a potentially life-threatening condition that can occur when selegiline is combined with drugs that raise serotonin levels. This includes SSRIs and SNRIs (common antidepressants), certain pain medications, and some over-the-counter cough medicines.

A survey of investigators in a major Parkinson’s research group identified 11 potential cases of serotonin syndrome among roughly 4,500 patients treated with selegiline and antidepressants (including SSRIs). An additional 17 published case reports described serotonin syndrome when an SSRI was combined with either selegiline or the related drug rasagiline. In most cases, symptoms resolved after one or both drugs were reduced or stopped, and none of the cases were fatal.⁸

There’s genuine debate in the field about how worried clinicians should be. Some pharmacologists have argued that the risk of serotonin toxicity with selective MAO-B inhibitors at standard doses is minimal and based largely on isolated case reports rather than systematic evidence, and that concern shouldn’t prevent clinicians from using these drugs in people who also need antidepressants.⁹ Others point out that the consequences of serotonin syndrome are severe enough that even a small risk merits caution. In practice, many doctors do combine selegiline with certain antidepressants, but with close monitoring and careful dose management.

Beyond prescription antidepressants, the interaction list extends to substances people might not think twice about. Suspected cases of serotonin toxicity have been reported when MAO inhibitors (including selegiline) are combined with dextromethorphan (found in many cough syrups), tramadol, meperidine (pethidine), methadone, and MDMA. Fatalities have been reported with some of these combinations, particularly meperidine and dextromethorphan in overdose.¹⁰ If you’re on selegiline, checking the label of any cold or cough remedy for dextromethorphan is a habit worth building, and you should always tell your doctor or pharmacist about selegiline before starting any new medication or pain treatment.

How the Transdermal Patch Changes the Side Effect Profile

Selegiline is available as a skin patch (the selegiline transdermal system, or STS), approved in the United States for major depression. Delivering the drug through the skin bypasses the gut and liver on the first pass, which has two important consequences: it avoids much of the tyramine interaction risk at lower patch doses (because gut MAO-A stays intact), and it produces far fewer of those amphetamine metabolites that cause insomnia and stimulant-type effects.

In a double-blind trial of the transdermal patch for major depression, the adverse event profile was essentially identical to placebo, with the notable exception of application-site skin reactions, which were more common with the active patch. No orthostatic or hypertensive reactions were observed.¹¹ A broader comparison of the transdermal system against oral MAO inhibitors and tricyclic antidepressants found that the patch produced significantly fewer side effect categories overall. Specifically, patients on the patch were less likely to report gastrointestinal problems compared to tricyclics and less likely to report cardiovascular side effects compared to oral MAOIs. The tradeoff was skin reactions, which were more common with the patch than with oral MAOIs. No serious adverse events were reported in the patch group.¹²

For the Parkinson’s population, an orally disintegrating tablet (ODT) form exists as well, designed to be absorbed partly through the lining of the mouth. This also reduces first-pass liver metabolism compared to a standard swallowed tablet, though not as completely as the patch. In clinical use, the ODT form has been described as safe and well tolerated in patients experiencing motor fluctuations.¹³

Liver and Kidney Function Matter More Than You’d Think

Because selegiline is so extensively metabolized by the liver, impaired liver or kidney function can dramatically change how much active drug (and how many metabolites) circulate in your body. Research measuring blood levels found that people with impaired liver function had roughly 18-fold higher selegiline exposure compared to controls, while people with impaired kidney function had about 6-fold higher levels. Elimination of the drug was substantially slower in both groups. These findings suggest that dose adjustments may be needed in anyone with compromised liver or kidney function.¹⁴

An 18-fold increase in drug exposure is enormous. It means that a standard dose in someone with significant liver disease could behave like a massive overdose in terms of blood levels, increasing the likelihood of every side effect on the list, from insomnia and blood pressure changes to loss of MAO-B selectivity. This isn’t always well communicated to patients, especially those with chronic liver conditions who may be prescribed selegiline without detailed pharmacokinetic discussion.

Impulse Control and Behavioral Changes

Impulse control disorders, such as compulsive gambling, binge eating, compulsive shopping, and hypersexuality, are an established risk with dopamine agonists used in Parkinson’s disease. Selegiline, which works differently (blocking dopamine breakdown rather than directly stimulating dopamine receptors), has generally been considered lower risk for these behaviors. However, case reports have documented impulse control disorders emerging after selegiline treatment in Parkinson’s patients.¹⁵ The mechanism probably relates to the increased dopamine availability that selegiline produces, even if the pathway differs from dopamine agonists. If you or someone close to you notices new compulsive behaviors after starting selegiline, it’s worth raising with your doctor rather than assuming the drug couldn’t be responsible.

Stopping Selegiline and Withdrawal Effects

Some people experience a noticeable sense of wellbeing on selegiline, and withdrawal symptoms have been reported when the drug is stopped.¹⁶ This isn’t surprising given the amphetamine metabolites and the general dopaminergic enhancement the drug provides. Withdrawal doesn’t appear to be as severe or as well-characterized as withdrawal from, say, SSRIs or benzodiazepines, but if you’ve been on selegiline for a while, a gradual taper rather than abrupt discontinuation is standard practice. The orthostatic hypotension effects, as discussed earlier, resolve fairly quickly after stopping, typically within a week.

The Mortality Controversy

In the mid-1990s, a British trial (the PDRG-UK study) reported higher mortality among Parkinson’s patients taking selegiline combined with levodopa compared to levodopa alone. This finding generated significant alarm and led some doctors to take patients off selegiline. But subsequent research told a different story. A meta-analysis pooling data from multiple trials found no increase in mortality associated with selegiline treatment, whether or not patients were also on levodopa. The death rate was about 11 per 1,000 patient-years in the selegiline group and about 14 per 1,000 patient-years in the non-selegiline group, with a hazard ratio close to 1.0 and no statistically significant difference.¹⁷

A separate observational study did find a non-significant 11% increase in death risk associated with selegiline use, with a somewhat larger signal in patients under 80 years of age and those taking selegiline without levodopa.¹⁸ The “non-significant” part is key: the confidence interval included zero, meaning the finding could easily reflect chance rather than a real effect. The consensus that has emerged over the years is that selegiline does not carry a meaningful mortality risk, but the controversy lingered long enough to make some clinicians wary. If someone mentions this concern to you, it’s worth knowing that the broader evidence base has been reassuring.

Safety in Adolescents

Selegiline has been studied in younger populations, though it’s not widely used in this group. In a double-blind trial of the transdermal patch for adolescent depression, side effect rates were similar between the active patch and placebo groups. The most common problems were application-site reactions, headache, and nausea, all of which occurred at roughly the same rate in both groups. No hypertensive crises were reported, and there were no concerning changes in lab work, vital signs, or heart rhythm monitoring.¹⁹

In studies comparing oral selegiline to methylphenidate for ADHD in children and adolescents, selegiline showed a tolerable side effect profile, with decreased appetite, difficulty falling asleep, and headaches observed more often in the methylphenidate group than in the selegiline group.²⁰ A separate trial in the same population reached a similar conclusion, describing selegiline as effective and well tolerated for ADHD.²¹ These are small studies and selegiline is not a standard ADHD treatment, but the data suggests it doesn’t introduce unusual safety problems in younger patients.

Practical Side Effect Management

Knowing what side effects exist is one thing; knowing what to actually do about them is another. A few practical points are worth keeping in mind if you’re taking selegiline or considering it:

Timing doses early: Taking selegiline in the morning and early afternoon (never at bedtime) reduces insomnia from the stimulant metabolites. This is the single most common and most effective piece of side effect management advice.
Position changes: Getting up slowly from sitting or lying down reduces the risk of dizziness or fainting from orthostatic hypotension, particularly if you’re also on levodopa or other medications that affect blood pressure.
Medication reviews: Tell every prescriber and pharmacist that you take selegiline. The list of potentially dangerous interactions is long enough that no one should be expected to memorize it. This includes over-the-counter cough medicines containing dextromethorphan.
Watch for behavioral changes: New impulsive behaviors, mood changes, or compulsive patterns are worth reporting even though they’re uncommon with selegiline specifically.
Patch-site rotation: If you use the transdermal system, rotating the application site helps reduce skin irritation, which is the most common patch-specific complaint.

The overall pattern with selegiline is that its side effects are manageable for most people when the drug is used at appropriate doses, the delivery method is matched to the clinical situation, and drug interactions are carefully screened. The problems tend to emerge when doses creep up, when liver or kidney function is compromised, or when other serotonergic or sympathomimetic drugs enter the picture without adequate attention to the interaction risk.